Stop with the big acquisitions for the American drug giant Pfizer, which after concluding some of the main 'mega-mergers' in the sector in recent years, prefers to focus on research alliances for the future. This was assured by Chief Executive Officer Ian Read on the occasion of the JP Morgan Global Healthcare Conference in San Francisco (USA).
Read said he was "very disinclined towards the possibility of further mergers". A sensitive change in Pfizer's corporate strategy, which in 10 years has merged with large companies such as Wyeth (2009), Pharmacia (2003) and Warner-Lambert (2000). "We will only make agreements that make financial sense – assured the CEO – of course, never say never, but it seems to me that we have the science we need and also the geographical spread".
According to Read, the drugs that will drive the growth of the New York company in the near term will be the anti-pneumococcal vaccine Prevnar 13, the anti-lung cancer Xalkori (crizotinib), axitinib for advanced renal cell carcinoma, tofacitinib for rheumatoid arthritis and the anti-thrombi Eliquis ( apixaban), which Pfizer owns in partnership with Bristol-Myers Squibb.
Barbara Di Chiara – January 13, 2012 – PharmaKronos
Ed.: Ian C. Read, 57 Years Old, Director, President and Chief Executive Officer Pfizer Inc. Compensation for 2010 $3,872,276.00 [source Forbes]
